Last Updated: 02/10/2025
Investigating the effect of CLK3 inhibitor on transmission stages of Plasmodium
Objectives
This research will aim to elucidate the effects of CLK3 inhibition on Plasmodium berghei and Plasmodium falciparum, with a particular focus on transmission stages. By understanding how CLK3 inhibition affects these key stages, the study aims to contribute to the development of new strategies for malaria control and ultimately reduce the disease’s burden.
Given the rising global incidence of malaria and increasing resistance to existing therapies, discovering new targets to disrupt the parasite’s lifecycle is imperative. Both in vitro and in vivo models will be employed to examine the efficacy of TCMDC-135051. The effect of the compound on the splicing in Plasmodium berghei will be analysed using RNA sequencing and bioinformatics tool. Through comprehensive optimisation, a high throughput protocol for analysing the ookinete conversion rate using ImageStream technology will be produced. Consequently, it will provide a time-efficient and cost-effective strategy for screening transmission blocking drugs. This research seeks to establish CLK3 inhibitors as a viable option in the fight against malaria, paving the way for new treatments that can effectively interrupt parasite transmission and help combat the growing challenge of drug resistance.
Oct 2024 — Sep 2027
Related Resources
